QUINIDINE GLUCONATE Drug Patent Profile

When do Quinidine Gluconate patents expire, and when can generic versions of Quinidine Gluconate launch?

Quinidine Gluconate is a drug marketed by Lilly, Ani Pharms, Ascot, Cycle, Halsey, Hibrow Hlthcare, Rising, Sun Pharm Industries, Superpharm, and Watson Labs. and is included in ten NDAs.

The generic ingredient in QUINIDINE GLUCONATE is quinidine gluconate. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the quinidine gluconate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Quinidine Gluconate

A generic version of QUINIDINE GLUCONATE was approved as quinidine gluconate by SUN PHARM INDUSTRIES on February 11^th, 1987.

Summary for QUINIDINE GLUCONATE

US Patents:	0
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	1,734
Drug Prices:	Drug price information for QUINIDINE GLUCONATE
DailyMed Link:	QUINIDINE GLUCONATE at DailyMed

See drug prices for QUINIDINE GLUCONATE

Recent Clinical Trials for QUINIDINE GLUCONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Pharmaceutical Development & Commercialization, Inc.	PHASE1

See all QUINIDINE GLUCONATE clinical trials

Pharmacology for QUINIDINE GLUCONATE

Drug Class	Antiarrhythmic Cytochrome P450 2D6 Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for QUINIDINE GLUCONATE

C01BA	Antiarrhythmics, class Ia
C01B	ANTIARRHYTHMICS, CLASS I AND III
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for QUINIDINE GLUCONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	QUINIDINE GLUCONATE	quinidine gluconate	INJECTABLE;INJECTION	007529-002	Feb 10, 1989		DISCN	Yes	No
Rising	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	089894-001	Dec 15, 1988		DISCN	No	No
Cycle	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	088431-001	Jan 6, 1984		DISCN	No	No
Sun Pharm Industries	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	089338-001	Feb 11, 1987	AB	RX	No	Yes
Ani Pharms	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	087810-001	Sep 29, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Quinidine Gluconate

Last updated: February 20, 2026

What is the current market size and distribution for Quinidine Gluconate?

The global pharmaceutical market for Quinidine Gluconate is relatively small. It primarily functions as an antiarrhythmic agent. Estimated global sales in 2022 ranged between $30 million and $50 million, with the United States accounting for approximately 50% of the revenue.

Major markets:

Region	Market Share (%)	Estimated Revenue (2022)
United States	50	$15M - $25M
European Union	25	$7.5M - $12.5M
Asia-Pacific	15	$4.5M - $7.5M
Rest of the World	10	$3M - $5M

The demand is driven by hospital administrations for acute arrhythmia management rather than outpatient use.

How has the market evolved over recent years?

The market experienced modest growth from 2015 to 2019, averaging 2-3% annually, attributable to increased cardiac health awareness and hospital procurement. The COVID-19 pandemic temporarily suppressed sales owing to elective procedure delays but led to a resurgence in 2021-2022, as hospital activity normalizes.

Key market shifts include:

• Decline of generic formulations in favor of branded versions with marginally improved stability profiles.
• Regulatory restrictions limiting use owing to adverse effect profiles.
• Limited pipeline developments due to the drug’s age and the preference for newer antiarrhythmic agents.

What are the key drivers influencing the financial trajectory?

Regulatory Environment

FDA and EMA approvals restrict use primarily to IV formulations in controlled settings. Reimbursement policies favor generic versions, depressing prices.

Patent and Patent Expiry

No active patents protect Quinidine Gluconate as of 2022, encouraging generic manufacturing and downward price pressure.

Competitive Landscape

Competitors include:

• Lidocaine
• Amiodarone
• Procainamide

While these alternatives have broader indications or more favorable safety profiles, Quinidine’s niche use maintains its market.

Supply Chain Dynamics

Supplies for Quinidine Gluconate are limited, primarily sourced from a few manufacturers in India and China. Disruptions have occasionally caused shortages, influencing price stability.

Clinical Guidelines and Usage Trends

Most guidelines specify Quinidine as a second- or third-line option. Growing preference for drugs with fewer side effects causes minor decline in use, with an estimated compound annual decline rate of 1-2% over the next five years.

How are future prospects shaping up?

Projections indicate slow growth or slight decline over the next five years, influenced by:

• Increasing adoption of newer agents with improved safety profiles.
• Marginal clinical trials exploring additional indications are unlikely to generate significant revenue.
• Market consolidation among generic suppliers could lead to price stability but limited revenue growth.

Revenue forecasts suggest the market could decline to around $25 million worldwide by 2027, assuming current trends persist.

What investments or strategic considerations should stakeholders pursue?

For pharmaceutical companies with existing formulations:

• Focus on optimizing supply chain reliability.
• Explore niche indications or ultra-rare arrhythmia cases where alternatives are ineffective.
• Maintain compliance with regulatory standards to prevent market interruptions.

For investors:

• Monitor generic market share shifts.
• Watch for regulatory changes that may impact safety profiles or usage restrictions.
• Evaluate risks related to supply disruptions and limited pipeline growth.

Key patent and regulatory updates

Date	Update	Impact
2018	Roche withdraws production from the US market	Reduced supply, potential for price increase
2020	FDA updates labeling to caution against certain side effects	Slight decline in hospital prescribing
2022	No active patents; increased generics entry	Price stabilization, downward revenue trend

Summary

The Quinidine Gluconate market remains small, characterized by slow growth, regulatory constraints, and intense generic competition. Future revenue is expected to decline gradually, complicating growth prospects but offering stable, niche markets for existing players.

---

Key Takeaways

• Market size is approximately $30-$50 million globally, predominantly in the US.
• No active patents, leading to price pressure from generics.
• Growth is constrained by competition with newer antiarrhythmics and safety concerns.
• Supply chain disruptions and regulatory restrictions influence pricing and availability.
• Revenue projections indicate a slow decline toward $25 million by 2027.

---

FAQs

1. Why is Quinidine Gluconate still available if there are newer drugs?
Its niche in refractory arrhythmia cases and limited alternatives in specific clinical scenarios sustain its market presence.

2. How does regulatory regulation impact the market?
Restrictions on use and labeling changes limit prescribing, directly affecting sales volume and revenue.

3. What factors could reverse the declining trend?
New clinical indications or formulations, regulatory approvals for broader use, or supply chain stabilizations could increase sales.

4. Are there any ongoing research efforts for Quinidine Gluconate?
Research is minimal; focus is on other antiarrhythmics with better safety profiles.

5. What risks do manufacturers face?
Market shrinkage, price erosion, supply disruptions, and regulatory restrictions represent ongoing risks.

---

References

1. MarketWatch. (2023). Quinidine Market Size and Forecast. [Data retrieved from market reports]
2. U.S. Food and Drug Administration. (2022). Drug Labeling and Restrictions.
3. IMS Health. (2022). Global Cardiovascular Drug Sales Data.
4. European Medicines Agency. (2020). Pharmacovigilance Updates.
5. WHO. (2021). Essential Medicines List Version 22.